Tacrolimus Envarsus Xr denied as non-formulary by Cigna?

Cigna's specific coverage criteria for tacrolimus envarsus xr are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied Tacrolimus Envarsus XR as Non-Formulary

A non-formulary denial means Envarsus XR (tacrolimus extended-release) is not included on Cigna's standard drug formulary for your specific plan. Cigna's formularies are plan-specific and tier-specific, so coverage of extended-release tacrolimus varies across employer groups and individual plans even within Cigna. When a drug is non-formulary, it is not automatically uncoverable — plans are required to have an exception process, and transplant immunosuppressants occupy a clinically unique position that supports exception requests.

A formulary exception based on medical necessity is a well-established pathway. The argument: formulary alternatives (typically immediate-release tacrolimus) are not clinically equivalent for your specific situation, making Envarsus XR the medically necessary choice.

## Your Federal Appeal Rights

• Formulary exception request: This is typically the first step and is separate from — but runs parallel to — a formal internal appeal. Cigna is required to have a process for exceptions to formulary decisions.
• Internal appeal (ACA §2719): If the exception request is denied, you have a right to internal appeal within the window stated on your denial notice.
• External review: Following a final internal denial, you may request independent external review, generally within approximately four months. Non-formulary denials that also constitute medical-necessity disputes are eligible for external review.
• ERISA §503: Employer-plan members are entitled to full-and-fair review, including written reasons and access to the criteria used.
• Expedited track: Request expedited review if ongoing access to your immunosuppression regimen is at risk.

## What to Gather

1. Formulary documentation: Obtain a copy of your plan's formulary and confirm which tacrolimus formulations are listed, at what tier, and under what conditions. 2. Transplant and diagnosis records: Documentation of your transplant type, date, and current immunosuppression history. 3. Tolerability and stability history: Records showing your clinical experience with formulary tacrolimus alternatives, including any variability, side effects, or adherence challenges. 4. Prescriber medical-necessity letter: Your transplant physician should explain why formulary alternatives are not clinically interchangeable for you specifically, referencing the FDA-approved prescribing information for Envarsus XR and the relevant transplant guideline organization.

## Criteria-Mapping Structure

Obtain Cigna's formulary exception criteria from your plan documents or Cigna's online portal. For each exception criterion, provide the corresponding documentation:

| Formulary Exception Criterion | Supporting Documentation | |---|---| | [Criterion from exception policy] | [Chart note / lab / prescriber letter reference] |

If your plan is governed by ERISA, note in your appeal letter that denial of a medically necessary, FDA-approved immunosuppressant based solely on formulary status — without a clinically grounded exception process — may not satisfy the plan's fiduciary obligations. This framing can be effective in prompting a more thorough review.